Treating COVID-19 with NRICM101 and NRICM102 - Author's reply
Pharmacol Res
.
2022 Nov:185:106438.
doi: 10.1016/j.phrs.2022.106438.
Epub 2022 Sep 9.
Authors
Sunny Jui-Shan Lin
1
,
Ming-Yung Lee
2
,
Yu-Hwei Tseng
3
,
Yi-Chang Su
4
Affiliations
1
Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
2
Department of Data Science and Big Data Analytics, Providence University, Taichung, Taiwan.
3
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan.
4
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan. Electronic address:
[email protected]
.
PMID:
36096422
PMCID:
PMC9461278
DOI:
10.1016/j.phrs.2022.106438
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Humans
SARS-CoV-2